 |
|
M. D. Anderson study finds strong relationship between high body mass index, pancreatic cancer
June 24, 2009Early age of excess weight associated with younger age of diagnosis; obesity before diagnosis linked to poor outcome
HOUSTON - In reviewing the weight history of pancreatic cancer patients across their life spans, researchers at The University of Texas M. D. Anderson Cancer Center have determined that a high body mass index in early adulthood may play a significant role in an individual developing the disease at an earlier age.
The study, published in the June 24 issue of the Journal of the American Medical Association, also found that patients who are obese the year before diagnosis have a poorer outcome than those who are not.
While excess weight is a known risk factor associated with pancreatic cancer, before now, few studies have looked at patients' body mass index (BMI) throughout their lifetime rather than simply at adulthood and/or year of disease diagnosis.
"This is the first study to explore at which ages excess body weight predisposes an individual to pancreatic cancer," said Donghui Li, Ph.D., professor in M. D. Anderson's Department of Gastrointestinal Medical Oncology and the study's corresponding author. "With our epidemiological research, we aimed to demonstrate the relationship between BMI and risk of pancreatic cancer across a patient's life span and determine if there was a time period that specifically predisposes an individual to the disease, as well as the link between BMI and cancer occurrence and overall survival of the disease."
Pancreatic cancer is the fourth leading cause of cancer death in men and women in this country. It is a highly lethal disease - according to the American Cancer Society, more than 42,470 persons will be diagnosed and 35,240 will likely die from the disease in 2009. The median survival for patients with the disease is less than 10 months and the five-year survival rate is less than five percent.
Obesity and smoking are the major modifiable risk factors associated with the disease; it's estimated that 25 percent of the pancreatic cancer cases are associated with the former and 27 percent with the latter, said Li. While the number of adults smoking is on the decline, the number of adults dangerously overweight is on the rise. In the U.S., obesity in adults has increased by 60 percent in the last 20 years, and is considered an epidemic by the Centers for Disease Control.
"With our study, we hoped to better understand the cause-and-effect relationship between this modifiable risk factor that contributes to the development of pancreatic cancer, in hopes that high-risk individuals can be identified and preventive measures discovered for this lethal disease," said Li.
For the case-control study, the researchers enrolled 1,595 individuals - 841 pancreatic adenocarcinoma patients treated at M. D. Anderson for their disease between 2004 and 2008, compared to 754 cancer-free individuals, all companions of M. D. Anderson patients. The groups were matched by age, race and sex. Using a detailed questionnaire, personal interviews were conducted to collect such information as their: smoking history; family history of cancer; alcohol use and general medical history. Participants also were asked to recall their height and body weights at ages 14-19; 20s; 30s; 40s; 50s; 60s; 70s; and the year prior to pancreatic cancer diagnosis or enrollment in the study.
Participants' BMI were then calculated at each age period and then classified by World Health Organization guidelines as either normal, overweight (greater than or equal to a score of 25, but less than 30) or obese (30 or greater). The researchers then compared the prevalence of overweight and obesity between both the patients and the controls. Among the cancer patients, they also compared the mean or median age of pancreatic cancer diagnosis and the overall survival time between those that were of normal weight, overweight and obese,.
While the research reconfirmed an association with obesity and pancreatic cancer, the study also found an association that excess at younger ages had a stronger association with increased risk of pancreatic cancer than subsequent increases in BMI. For example, individuals overweight at 14-19 and/or in their 30s had a 60 percent increased risk of the disease. Those obese at age 20s-40s were found to have a 2-3 times higher risk of pancreatic cancer. The risk of developing the disease appeared to level off for those that gained excess weight in their 40s; and after age of 50, the risk for the disease was not statistically significant.
Another major finding was the association between excess weight and earlier onset of pancreatic cancer. The study found a median age at diagnosis of 64 for those at normal weight, compared to 61 and 59 for overweight and obese patients respectively.
"This is one of the most surprising findings," said Li "On average, overweight pancreatic cancer patients were diagnosed two to three years earlier, and obese patients were diagnosed five to six years earlier, which underscores the impact of obesity on loss of life - especially in productive years."
The researchers also found that obesity later in life, especially within a year prior to a patient's cancer diagnosis, was associated with a reduced overall survival time. For example, said Li, in the study population, patients with a healthy body weight had an average survival time of 18 months, compared to 13 months for both overweight and obese patients.
"As we see obesity dangerously on the rise in the country, this study has true public health implications. Like smoking, obesity is a modifiable risk factor," said James Abbruzzese, M.D., professor and chair of the Department of Gastrointestinal Medical Oncology and the last author on the study. "Our study suggests that weight control at a younger age should be the primary preventive strategy to reduce the risk of pancreatic cancer."
The study may even have clinical implications, especially in regard to poor survival and obesity the year before diagnosis, as this association could affect pancreatic cancer clinical trial stratification in the future, explained Abbruzzese.
As future research, the researchers plan to further investigate the link between obesity, pancreatic cancer and poor outcome, looking at insulin resistance as a possible mechanism. Li and her team will also research what factors - genetic, dietary or others - modify the risk between excess body weight and the disease, in hopes of one day developing preventive strategies and discovering biomarkers for early detection of the disease.
University of Texas M. D. Anderson Cancer Center
"This is the first study to explore at which ages excess body weight predisposes an individual to pancreatic cancer," said Donghui Li, Ph.D., professor in M. D. Anderson's Department of Gastrointestinal Medical Oncology and the study's corresponding author. "With our epidemiological research, we aimed to demonstrate the relationship between BMI and risk of pancreatic cancer across a patient's life span and determine if there was a time period that specifically predisposes an individual to the disease, as well as the link between BMI and cancer occurrence and overall survival of the disease."
Pancreatic cancer is the fourth leading cause of cancer death in men and women in this country. It is a highly lethal disease - according to the American Cancer Society, more than 42,470 persons will be diagnosed and 35,240 will likely die from the disease in 2009. The median survival for patients with the disease is less than 10 months and the five-year survival rate is less than five percent.
Obesity and smoking are the major modifiable risk factors associated with the disease; it's estimated that 25 percent of the pancreatic cancer cases are associated with the former and 27 percent with the latter, said Li. While the number of adults smoking is on the decline, the number of adults dangerously overweight is on the rise. In the U.S., obesity in adults has increased by 60 percent in the last 20 years, and is considered an epidemic by the Centers for Disease Control.
"With our study, we hoped to better understand the cause-and-effect relationship between this modifiable risk factor that contributes to the development of pancreatic cancer, in hopes that high-risk individuals can be identified and preventive measures discovered for this lethal disease," said Li.
For the case-control study, the researchers enrolled 1,595 individuals - 841 pancreatic adenocarcinoma patients treated at M. D. Anderson for their disease between 2004 and 2008, compared to 754 cancer-free individuals, all companions of M. D. Anderson patients. The groups were matched by age, race and sex. Using a detailed questionnaire, personal interviews were conducted to collect such information as their: smoking history; family history of cancer; alcohol use and general medical history. Participants also were asked to recall their height and body weights at ages 14-19; 20s; 30s; 40s; 50s; 60s; 70s; and the year prior to pancreatic cancer diagnosis or enrollment in the study.
Participants' BMI were then calculated at each age period and then classified by World Health Organization guidelines as either normal, overweight (greater than or equal to a score of 25, but less than 30) or obese (30 or greater). The researchers then compared the prevalence of overweight and obesity between both the patients and the controls. Among the cancer patients, they also compared the mean or median age of pancreatic cancer diagnosis and the overall survival time between those that were of normal weight, overweight and obese,.
While the research reconfirmed an association with obesity and pancreatic cancer, the study also found an association that excess at younger ages had a stronger association with increased risk of pancreatic cancer than subsequent increases in BMI. For example, individuals overweight at 14-19 and/or in their 30s had a 60 percent increased risk of the disease. Those obese at age 20s-40s were found to have a 2-3 times higher risk of pancreatic cancer. The risk of developing the disease appeared to level off for those that gained excess weight in their 40s; and after age of 50, the risk for the disease was not statistically significant.
Another major finding was the association between excess weight and earlier onset of pancreatic cancer. The study found a median age at diagnosis of 64 for those at normal weight, compared to 61 and 59 for overweight and obese patients respectively.
"This is one of the most surprising findings," said Li "On average, overweight pancreatic cancer patients were diagnosed two to three years earlier, and obese patients were diagnosed five to six years earlier, which underscores the impact of obesity on loss of life - especially in productive years."
The researchers also found that obesity later in life, especially within a year prior to a patient's cancer diagnosis, was associated with a reduced overall survival time. For example, said Li, in the study population, patients with a healthy body weight had an average survival time of 18 months, compared to 13 months for both overweight and obese patients.
"As we see obesity dangerously on the rise in the country, this study has true public health implications. Like smoking, obesity is a modifiable risk factor," said James Abbruzzese, M.D., professor and chair of the Department of Gastrointestinal Medical Oncology and the last author on the study. "Our study suggests that weight control at a younger age should be the primary preventive strategy to reduce the risk of pancreatic cancer."
The study may even have clinical implications, especially in regard to poor survival and obesity the year before diagnosis, as this association could affect pancreatic cancer clinical trial stratification in the future, explained Abbruzzese.
As future research, the researchers plan to further investigate the link between obesity, pancreatic cancer and poor outcome, looking at insulin resistance as a possible mechanism. Li and her team will also research what factors - genetic, dietary or others - modify the risk between excess body weight and the disease, in hopes of one day developing preventive strategies and discovering biomarkers for early detection of the disease.
University of Texas M. D. Anderson Cancer Center
Pancreatic Cancer Current Events and Pancreatic Cancer News RSSAfrican-Americans with colorectal cancer have poorer outcomes, lower survival rates
New research published in the November issue of the Journal of the American College of Surgeons shows that African-American patients with colorectal cancer are more likely to be diagnosed with advanced disease and are less likely to undergo surgical procedures compared with Caucasians, suggesting that improvements in screening and rates of operation may reduce differences in colorectal cancer outcomes for African-Americans.
Discovery offers potential new pancreatic cancer treatment
Tiny particles that can carry drugs and target cancer cells may offer treatment hope for those suffering with pancreatic cancer. New research to be presented in November at the American Association of Pharmaceutical Scientists (AAPS) Annual Meeting in Los Angeles reveals that tumor-penetrating microparticles (TPM) have been specifically designed to break through hard-to-infiltrate barriers and deliver drugs more effectively and efficiently than the standard form of chemotherapy such as those injected through a vein.
Hepatitis B does not increase risk for pancreatic cancer
A Henry Ford Hospital study found that hepatitis B does not increase the risk for pancreatic cancer - and that only age is a contributing factor.
M. D. Anderson examines use of toad venom in cancer treatment
Huachansu, a Chinese medicine that comes from the dried venom secreted by the skin glands of toads, has tolerable toxicity levels, even at doses eight times those normally administered, and may slow disease progression in some cancer patients, say researchers from The University of Texas M. D. Anderson Cancer Center.
Pancreatic cancer: Researchers find drug that reverses resistance to chemotherapy
For the first time researchers have shown that by inhibiting the action of an enzyme called TAK-1, it is possible to make pancreatic cancer cells sensitive to chemotherapy, opening the way for the development of a new drug to treat the disease.
Endothelin-1 inhibitors in chronic pancreatitis
Fibrosis is a key feature of chronic pancreatitis and pancreatic cancer. The extensive deposition of extracellular matrix proteins fosters the development of an exocrine and endocrine organ insufficiency, and accelerates progression of the tumour.
Autoimmune response can induce pancreatic tumor rejection
Immune responses are capable of killing tumors before they can be directed toward normal body tissue, according to new scientific findings published in Cancer Research, a journal of the American Association for Cancer Research.
MicroRNAs circulating in blood show promise as biomarkers to detect pancreatic cancer
A blood test for small molecules abnormally expressed in pancreatic cancer may be a promising route to early detection of the disease.
Blood-flow metabolism mismatch predicts pancreatic tumor aggressiveness
Researchers from Turku, Finland, have identified a blood-flow glucose consumption mismatch that predicted pancreatic tumor aggressiveness, according to results of a study published in Clinical Cancer Research, a journal of the American Association for Cancer Research.
Taking the Needle's Sting Out of Diabetes
Found in 30% of all human cancer tumors, the Ras protein literally "drives cells crazy," says Prof. Yoel Kloog, the dean of the Faculty of Life Sciences at Tel Aviv University. Prof. Kloog was the first in the world to develop an effective anti-Ras drug against pancreatic cancer, currently in clinical trials.
More Pancreatic Cancer Current Events and Pancreatic Cancer News Articles
 |
100 Questions & Answers About Pancreatic Cancer, Second Edition by Eileen O'Reilly (Author), Joanne Frankel Kelvin (Author) Whether you re a newly diagnosed pancreatic cancer patient, a survivor, or a friend or relative of someone with pancreatic cancer, this book offers help. The only text to provide a doctor s and patient s view, 100 Questions & Answers About Pancreatic Cancer, Second Edition gives you authoritative, practical answers to your questions about treatment options, post-treatment quality of life, sources of support, and much more. The authors, a medical oncologist and a nurse with 25 years of experience with cancer patients, provide a comprehensive, step-by-step discussion of what you can expect in the diagnosis and treatment of pancreatic cancer, while patient commentaries provide a real-life understanding of what these steps might mean for your day-to-day life. This book is an invaluable... |
 |
Pancreatic Cancer (M.D. Anderson Solid Tumor Oncology Series) by Andrew M. Lowy (Editor), Steven D. Leach (Editor), Philip Philip (Editor) Since the previous M.D. Anderson Solid Tumor Oncology Series publication on pancreatic cancer, there have been major advances in our understanding of molecular events which underlie pancreatic cancer development, both in the sporadic and inherited forms. We have seen the development of the first mouse models that accurately recapitulate features of the human disease. Several landmark clinical trials in both resectable and metastatic pancreatic cancer have been completed, raising new questions about the standard of care in this disease. Finally, the era of targeted biologic therapies has engendered new excitement about the prospects of more rapid progress in understanding and successfully treating this dreadful disease. Therefore, it is an appropriate time to review these important... |
 |
100 Q&A About Pancreatic Cancer (100 Questions & Answers) by Joanne Frankel Kelvin Eileen O'Reilly (Author) EMPOWER YOURSELF! Whether you’re a newly diagnosed pancreatic cancer patient, a survivor, or a friend or relative of someone with pancreatic cancer, this book offers help. The only text to provide a doctor’s and patient’s view, 100 Questions & Answers About Pancreatic Cancer gives you authoritative, practical answers to your questions about treatment options, post-treatment quality of life, sources of support, and much more. The authors, a medical oncologist and a nurse with 25 years of experience with cancer patients, provide a comprehensive, step-by-step discussion of what you can expect in the diagnosis and treatment of pancreatic cancer, while patient commentaries provide a real-life understanding of what these steps might mean for your day-to-day life. This book is an... |
 |
My Journey With Pancreatic Cancer by Calvin Rains (Author) This book is shared to help all understand the cancer affecting the pancreas which is a vital organ in the digestion of food. Pancreatic cancer is one of the most deadly of cancers affecting the human body. Less than 5% of those diagnosed with Pancreatic Cancer survive the first year.This book is intended to help the patient, their families, and friends to understand the dangers and possible treatments. It is vital that the patient and their families understand the importance of choices of treatment and the possible side effects.This is basically a diary of one patient who has been able to survive five (5) years at this writing. The road can be challenging, but healing is possible if discovered and treated quickly. This book will help the patient and their families to better deal with... |
 |
Pancreatic Cancer by Daniel D. Von Hoff (Editor) (Author) Praise for the book “An outstanding text covering all aspects of pancreatic cancer, from embryology through genetics and pathology, and including all avenues of treatment. There are 112 internationally recognized authors, the book is marvelously illustrated, and is a must for all scientists and clinicians interested in neoplasms of the pancreas. It is currently the most up-to-date and complete text on pancreatic cancer available.” -- John L. Cameron, MD The Alfred Blalock Distinguished Service Professor The Johns Hopkins University School of Medicine |
 |
Clearly Charming Purple Ribbon Pancreatic Cancer, Fibromyalgia, Lupus Italian Charm by Clearly Charming Purple ribbon stands for domestic violence, pancreatic cancer, Chrons Disease and colitis, Cystic Fibrosis, Fibromyalgia, and Lupus awareness. It will make a great addition to your Italian charm bracelet or a perfect personalized gift. Commemorate special occasions, capture memorable moments, or simply show off your birthstone by creating your own original Italian charm bracelet. Add Clearly Charming premium quality interlocking modular Italian charm links to your Italian Charm Bracelet and create your own memory bracelet. |
 |
Cancer Be Gone Guided imagery CD taps into the immense power of the mind to enhance comfort, healing, an optimistic attitude and positive expectations. Metaphor of "cancer as weeds in a garden that are easily managed". |
 |
Beating Pancreatic Cancer Together T-shirt Large White by Shop Zeus |
 |
Pancreatic Cancer Awareness Ribbon Mouse Pad by MyHeritageWear.com The Pancreatic Cancer Ribbon proudly displayed on a mouse pad. There is no better way to achieve awareness for the meaning of the Pancreatic Cancer Ribbon than to display it on your mouse pad for everyone to see. The mouse pad measures at 9.25 x 7.75, it is machine washable, and the colors will not fade or run. Start gaining awareness today by presenting your Pancreatic Cancer Ribbon mouse pad at work or at home. It is certain to keep your mouse rolling in style all while gaining support and awareness! |
|
Hope Springs for Pancreatic Cancer by Expressions from the Heart Designed with gift giving and memento keeping in mind, each mouth-blown, glass, heart-shaped ornament features a waffle-like texture into which 160 Swarovski crystals are set. The evocative line offers a fresh and very sentimental option for ornament lovers seeking an alternative to just another tree trimming collectible. Each spectacular piece is suspended from an elegant, bow-trimmed, ribbon and comes packaged, for giving and keeping, in a lovely, high-quality box. Each design has its own special name, accompanied by an evocative story, presented on a story card within the gift box. |
| © 2009 BrightSurf.com |